Neoparin Multi (Enoxaparin Sodium)

Enoxaparin Sodium, the active ingredient in Neoparin Multi, is a low molecular weight heparin presented as a sterile injectable solution for subcutaneous, intravenous, and haemodialysis use. It is employed to prevent and treat thrombo‑embolic disorders in patients at risk of clot formation. GNH USA supplies Neoparin Multi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Enoxaparin Sodium is a low molecular weight heparin used in the prevention and treatment of venous thrombo‑embolism. - Deep vein thrombosis (DVT) prophylaxis in surgical patients: reduces the incidence of postoperative clot formation. - Acute deep vein thrombosis treatment: facilitates clot resolution and prevents extension. - Pulmonary embolism prevention and treatment: lowers the risk of life‑threatening embolic events. - Anticoagulation during haemodialysis: maintains circuit patency and prevents clotting during treatment.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the administration site. - Bruising or hematoma: localized bleeding under the skin. - Nausea or vomiting: gastrointestinal upset. - Headache or dizziness: transient neurologic symptoms. - Mild bleeding (e.g., gum, epistaxis): minor hemorrhagic events.

Serious or Rare Side Effects: - Major bleeding: internal hemorrhage requiring medical intervention. - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet drop. - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Skin necrosis at injection sites: severe local tissue damage. - Spinal or epidural hematoma: rare but serious neurologic complication. - Elevated liver enzymes: abnormal hepatic function tests.

Careful assessment is required before initiating therapy with Enoxaparin Sodium. - Renal impairment: dose adjustment may be needed in patients with reduced clearance. - Hepatic disease: monitor coagulation parameters in severe liver dysfunction. - Concomitant anticoagulants or antiplatelet agents: increased bleeding risk. - Recent surgery or trauma: evaluate bleeding risk before administration. - Pregnancy and breastfeeding: safety not established; use only if benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin Sodium can interact with several drug classes, influencing bleeding risk or anticoagulant effect.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, direct thrombin inhibitors): additive anticoagulation. - Antiplatelet drugs (e.g., aspirin, clopidogrel): heightened hemorrhagic potential. - Fibrinolytic agents (e.g., alteplase): synergistic clot‑dissolving effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased mucosal bleeding. - Spinal or epidural anesthesia: risk of spinal hematoma.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible additive hypotensive effect. - Diuretics: monitor renal function and electrolytes. - Certain antibiotics (e.g., vancomycin, quinolones): may alter platelet function. - Hormonal contraceptives: modest increase in thrombotic risk. - Lipid‑lowering agents (e.g., statins): monitor for rare bleeding events.